Indications for CLEOCIN INJECTION:
Serious susceptible infections where less toxic antibiotics are inappropriate, including respiratory, skin and soft tissue, septicemia, intraabdominal, female pelvic or genital; bone and joint (inj).
Serious: 0.6–1.2g daily. More severe: 1.2–2.7g/day IM or IV. Both: give in 2–4 equally divided doses; max 600mg per IM inj and 4.8g/day IV. Beta-hemolytic streptococcal infections: treat for at least 10 days.
Neonates: 15–20mg/kg per day. >1 month: 20–40mg/kg per day IM or IV. Both: give in 3–4 equally divided doses. Or: serious infections: 350mg/m2 per day; more severe: 450mg/m2 per day. Beta-hemolytic streptococcal infections: treat for at least 10 days.
C. difficile-associated diarrhea.
Risk of C. difficile-associated diarrhea; discontinue and treat if colitis is suspected or confirmed. Reserve use for serious infections. Not for treatment of meningitis. Permanently discontinue if severe hypersensitivity reactions occur. Allergy. Asthma (75mg, 150mg caps). GI disease (esp. colitis). Atopy. Monitor blood, renal, and hepatic function in long-term use and in children. IV: Gasping syndrome (neonates, infants). Elderly. Pregnancy. Nursing mothers: consider alternative drug.
May potentiate neuromuscular blocking agents; caution. May be potentiated by strong CYP3A4 inhibitors; monitor. May be antagonized by strong CYP3A4 inducers (eg, rifampicin); monitor. May antagonize erythromycin; avoid. Antiperistaltic agents may worsen colitis.
Pseudomembranous colitis, C. difficile-associated diarrhea, nausea, vomiting, abdominal pain, dysguesia, rash, pruritus, angioedema, anaphylaxis, jaundice, renal dysfunction, blood dyscrasias, polyarthritis, severe skin reactions (eg, toxic epidermal necrolysis, erythema multiforme, drug reaction with eosinophilia and systemic symptoms, Stevens-Johnson syndrome).
Caps—100; Granules (100mL)—1; Inj (2mL, 4mL, 6mL vials)—25